U.S. Commercial Market Assessment
Evaluate target segments, specialties, customers, competitors, buying committees, current visibility, proof, customer questions, direct-versus-distributor considerations, market-development needs, content gaps, and existing marketing infrastructure. Identify what can transfer, what needs adaptation, and which unknowns require research.
U.S. Positioning, Product Marketing & Messaging
Adapt positioning, value propositions, stakeholder messaging, corporate story, product architecture, proof hierarchy, and competitive context for U.S. physicians, hospital buyers, distributors, patients, or other audiences. Voice-of-customer research can validate the story before broader execution.
Go-to-Market & Launch Readiness
Sequence brand and product messaging, websites, sales materials, HCP or patient education, content, media, trade shows, PR, demand generation, CRM, lead handling, distributor activation, measurement, and other dependencies around the commercial model, regulatory timing, budget, channel strategy, and launch milestones.
U.S. Sales, Distributor & Channel Enablement
Build U.S.-specific presentations, product collateral, clinical and technical communication, comparisons, buyer FAQs, distributor toolkits, product training, trade-show materials, digital follow-up, account resources, partner onboarding, co-marketing, campaigns, lead routing, and channel communication.
Digital Presence, Demand & Market Visibility
Create the U.S. digital and commercial infrastructure across website strategy, SEO, AI search, paid media, email, social, content, webinars, HCP or DTP programs, CRM architecture, territory routing, lifecycle definitions, nurture, event follow-up, attribution, dashboards, and lead-management processes.
Effective U.S. commercialization requires alignment across leadership, marketing, sales, clinical, channel, and investor stakeholders around market entry strategy, launch readiness, commercial infrastructure, and the path to scalable growth.
International Founders & Executive Teams
Need a realistic view of U.S. opportunity, investment requirements, commercialization sequence, organizational readiness, and the decisions that should be made before launch spending accelerates.
Marketing & Commercial Leaders
Need U.S.-specific positioning, go-to-market strategy, channels, budgets, demand infrastructure, launch planning, review workflows, and measurement.
Sales & Business Development Teams
Need market-specific messaging, sales materials, account strategy, CRM processes, event support, distributor coordination, and qualified market engagement.
Product, Clinical & Medical Teams
Help ensure U.S. communication reflects product evidence, workflow, patient or customer fit, training needs, recurring questions, and the practical realities of adoption.
Distributors & Channel Partners
May become central to market coverage and need onboarding, enablement, localization, training, demand support, lead management, and a clear manufacturer support model.
Teams Investors & Boards
Need visibility into commercialization readiness, market assumptions, investment priorities, milestones, early market response, and the path from entry to scalable growth.
A company can understand its technology exceptionally well and still underestimate how much of the commercial model needs to change for the United States. Launching before those questions are resolved often creates avoidable rework across websites, sales materials, distributor support, campaigns, events, CRM, and follow-up.
International Success Does Not Automatically Transfer
The Commercial Model Is Not Yet Clear
Positioning Was Built for Another Market
Regulatory Milestones Are Mistaken for Commercial Readiness
Sales, Distribution & Marketing Are Planned Independently
Infrastructure Lags Behind Demand
Evaluate the U.S. market, audiences, competitors, positioning, commercial model, digital presence, sales readiness, channel options, and marketing infrastructure.
Evaluate the U.S. market, audiences, competitors, current positioning, commercial model, digital presence, sales readiness, channel options, and marketing infrastructure.
Test the most important market, buyer, positioning, channel, and commercialization assumptions through research, stakeholder input, available data, and competitive context.
Adapt the product story, value hierarchy, proof, messaging, sales narrative, and digital experience around the U.S. stakeholders responsible for evaluation and adoption.
Build the launch roadmap, CRM and lead workflows, sales or distributor enablement, campaigns, events, content, review process, and measurement before activation scales.
Activate the coordinated U.S. program across sales, channel, digital, HCP or patient marketing, PR, events, content, and demand-generation touchpoints.
Use customer conversations, sales feedback, digital performance, account engagement, channel response, and market learning to strengthen the program and guide additional investment.
U.S. market entry can break down at any point in the commercialization journey. A company may see strong market potential but enter before its positioning, sales model, or infrastructure is ready. A launch may generate early attention without enough follow-up, channel support, or market-specific education to convert interest into adoption. Initial traction can also stall when customer feedback, sales learning, and performance data are not translated into a stronger commercial approach.
U.S. commercialization strategy helps strengthen each stage of that journey so MedTech companies can reduce entry risk, improve launch coordination, accelerate market learning, and build a more scalable path to adoption and growth.
Connect market research, positioning, go-to-market strategy, sales and distributor enablement, digital marketing, CRM, events, communications, and growth execution around your U.S. commercialization plan.
Get clear answers to common questions about medical device U.S. market entry, from commercialization planning and localization to channel strategy, regulatory boundaries, trade shows, ongoing marketing support, and performance measurement.
A U.S. market entry partner helps an international medical device company understand and prepare for the commercial requirements of entering the United States. For Icovy, that includes market and customer research, positioning, product marketing, go-to-market planning, launch readiness, digital strategy, sales enablement, distributor support, HCP or patient marketing, demand generation, CRM, events, PR, content, and measurement.
Icovy supports the marketing and commercialization side of U.S. entry. We can plan around regulatory timing, approved claims, review processes, and communication requirements established by the client. Formal FDA regulatory strategy, submissions, quality systems, legal advice, and other regulatory responsibilities should remain with the client's qualified internal or external specialists.
Icovy can support the commercial and marketing analysis surrounding channel choices, including customer segments, buying process, geographic coverage, marketing requirements, sales support, partner enablement, and the infrastructure each model would require. Final decisions may also depend on legal, tax, contracting, reimbursement, operational, and regulatory factors that require input from the appropriate specialists.
Yes. Localization can involve more than translation. We can evaluate market positioning, value propositions, terminology, buyer expectations, product-page structure, content, sales materials, proof, campaigns, events, search behavior, and digital journeys for U.S. audiences. The objective is to preserve useful global brand equity while adapting the commercial communication where the U.S. market requires it.
Commercial planning should usually begin before the company is ready to activate broad market-facing promotion because research, positioning, website work, sales enablement, distributor onboarding, CRM, content, review processes, and launch planning all require lead time. The exact timing depends on regulatory status, product maturity, funding, commercial model, and what the company is permitted to communicate at each stage.
Yes. Trade shows can support market education, customer discovery, distributor conversations, media, product launch, sales meetings, and lead generation when they are connected to the broader entry plan.Icovy can support booth strategy, event marketing, meetings, sales materials, PR, media, travel and logistics, onsite content, lead capture, CRM, and post-event follow-up.
Yes. A market-entry engagement can transition into an integrated growth partnership or fractional marketing leadership model when the company needs continued U.S. strategy and execution.That can reduce the need to assemble separate partners for digital, content, CRM, events, creative, PR, sales enablement, HCP marketing, and other commercialization workstreams.
Early-stage measurement may focus on commercial readiness, target-account engagement, search visibility, content response, event activity, distributor participation, lead quality, sales conversations, CRM progression, and other indicators available before revenue becomes predictable. As the U.S. business matures, the measurement model can expand toward qualified pipeline, customer acquisition, account penetration, product adoption, channel performance, and other commercial outcomes supported by reliable data.